Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.
The Lancet. Neurology（2023）
摘要
Minoryx Therapeutics.
更多查看译文
关键词
leriglitazone,efficacy,double-blind,multi-centre,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要